Results 51 to 60 of about 5,352 (210)

Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir [PDF]

, 2021
Objectives Cobicistat and ritonavir have different inhibitory profiles for drug transporters that could impact the distribution of co-administered drugs.
Bartels, Hanni, Decosterd, Laurent, Battegay, Manuel, Marzolini, Catia   +3 more
core  

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

BMC Nephrology, 2020
Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).
José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó   +7 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3656-3665, October 2026.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Aspectos farmacológicos de darunavir/cobicistat

Enfermedades Infecciosas y Microbiología Clínica, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad bien conocido.
González-Doménech, Carmen María, Palacios-Muñoz, María Rosario, Santos-González, Jesús Leandro   +2 more
openaire   +3 more sources

Factors associated with the number of drugs in darunavir/cobicistat regimens. [PDF]

, 2019
Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens.
Knobel, Hernando, Torralba, Miguel, Negredo, Eugenia, Boix, Vicente, Martinez, Esteban, González-Doménech, Carmen María, Ocampo, Antonio, Payeras, Antoni, Alejos, Belén, Martin-Carbonero, Luz, Pérez-Elías, María Jesús, Lozano, Fernando, Montero, Marta, Gutierrez, Mar, Sanz, José, González-Cordón, Ana, Garcia-Fraile, Lucio   +16 more
core   +1 more source

Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Suzetrigine (VX‐548) is a first‐in‐class, oral, non‐opioid, FDA‐approved analgesic for the treatment of moderate to severe acute pain. Based on Phase 1 clinical drug–drug interaction (DDI) studies, suzetrigine is a weak‐to‐moderate cytochrome P450 3A (CYP3A) inducer and thus has the potential to decrease exposure and impact efficacy of CYP3A ...
Guanyu Wang, Elizabeth Lakota, Bo Feng, Licong Jiang, Guiqing Liang, Brian Hare   +5 more
wiley   +1 more source

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Drugs in Context, 2019
The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to ...
Melissa E Badowski, Bradley Burton, Kristy M Shaeer, John Dicristofano   +3 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, Volume 27, Issue 9, Page 1399-1420, September 2026.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications [PDF]

, 2021
Nearly all HIV PIs and the integrase inhibitor elvitegravir require a pharmacokinetic enhancer in order to achieve therapeutic plasma concentrations at the desired dose and frequency. Whereas ritonavir has been the only available pharmacokinetic enhancer
Back, David, Gibbons, Sara, Marzolini, Catia, Khoo, Saye   +3 more
core  

Thai Transplant Care Practice Guideline on Immunosuppressive Therapy for Adult Kidney Transplantation

Nephrology, Volume 31, Issue S2, September 2026.
ABSTRACT The Thai Transplantation Society developed these clinical practice guidelines to establish a comprehensive standard for immunosuppressive therapy in adult kidney transplantation. While rooted in evidence‐based medicine, the objective of this document extends beyond local application, serving as a practical model for low‐to‐middle‐income ...
Suwasin Udomkarnjananun, Napun Sutharattanapong, Nuttasith Larpparisuth, Korntip Phonphok, Tanun Ngamvichchukorn, Peenida Skulratanasak, Pitchamon Inkong, Suwikran Wongpraphairot, Opas Traitanon, Piyavadee Homkrailas, Kajohnsak Noppakun, Natavudh Townamchai, on behalf of Thai Transplantation Society   +12 more
wiley   +1 more source